Eli Lilly and Company

Deciphera Pharmaceuticals, LLC

Audion Therapeutics

Philip Arthur Hipskind

Karen Lynn Lobb

James Arthur Nixon

Takako Takakuwa

J Jeffry Howbert

Brian Stephen Muehl

Cynthia Darshini Jesudason

Richard Todd Pickard

Robert Alan Gadski

Lisa Selsam Beavers

Sung Y Cho

Takako Wilson (nee Takakuwa)

Thomas Alan Crowell

Joseph H Krushinski, Jr

Bruce D Gitter

William Joseph Hornback

Don Richard Finley

Daniel Jon Sall

Chuan Shih

Ho-Shen Lin

Jolie Anne Bastian

Chafiq Hamdouchi

Bharvin Kumar Patel

Cora Sue Grossman

Julia Marie Clay

Craig William Lindsley

Daniel L Flynn

Dennis Michael Zimmerman

Paul Leslie Ornstein

Michael D Kaufman

Thomas Charles Britton

Michael Enrico Richett

Stephen W Kaldor

Hamideh Zarrinmayeh

James Robert Henry

Guoxin Zhu

James E Fritz

Lakshminarayana Vogeti

Scott Eugene Conner

Edward C R Smith

Robert F Bruns, Jr

Jose Eduardo Lopez

Erik James Hembre, Ii

Jianliang Lu

Bryan D Smith

Sheng-Bin Peng

Mary Margaret Mader

Terry Patrick Finn

Alfonso De Dios

Grant Mathews Vaught

Beatriz Lopez De Uralde Garmendia

Aaron David Wrobleski

Michelle Lee Thompson

Elizabeth Aaron Collins

Scott Wise

Wei-Ping Lu

John M Schaus

Jeffrey A Dodge

Michael J Martinelli

John Michael Morin, Jr

Albert Edge

Theo Schotten

Brian Morgan Watson

Kenneth Allen Savin

Richard Craig Thompson

Michael Dean Kinnick

Thomas Hughes Corbett

Nancy June Snyder

Ling Liu

Bret E Huff

Jeffrey Daniel Cohen

Lawrence Joseph Heinz, Ii

Donald R Gehlert

Gregory Alan Stephenson

Richard Duane Johnston

Zhaogen Chen

Freddie Craig Stevens

Timothy Malcolm Caldwell

Buddy Eugene Cantrell

Gaiying Zhao

Michael A Staszak

James Ronald Gillig

William C Patt

Renhua Li

Jianke Li

Mark Donald Chappell

James Lee Toth

Jason Eric Lamar

Michael Alan Robertson

James Denmore Copp

Allie Edward Tripp

Jason Kenneth Myers

Yiqing Feng

Francis O Ginah

Michael John Rupp

James Jeffry Howbert

Yen-Shi Lai

Carsten Ott

Takako Wilson

Jochen Ammenn

Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.

MET antibody drug conjugates

The present invention provides the following compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing said compounds useful as a Notch pathway signaling inhibitor for the treatment of named cancers, sensorineural hearing loss caused by auditory hair cell loss, and inducing auditory hair cell generation. 

Notch pathway signaling inhibitor compounds

This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers. 

RAF inhibitor compounds

This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers. 

Raf inhibitor compounds

The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.

Disubstituted phthalazine hedgehog pathway antagonists

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. 

Glucagon receptor antagonists, preparation and therapeutic uses

The present invention provides a compound, or a pharmaceutically acceptable salt or hydrate, and a pharmaceutical composition containing said compound, or a pharmaceutically acceptable salt or hydrate, useful as a Notch pathway signaling inhibitor for the treatment of cancer.

Notch pathway signaling inhibitor compound

The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C&#x2014;Ror N; Ris hydrogen, fluoro or cyano; Ris formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; Ris methyl or trifluoromethyl; Ris pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; Ris trifluoromethyl or methylsulfonyl; Ris hydrogen or methyl; and R, R, R, Rand Rare independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R, R, R, Rand Rare hydrogen useful in the treatment of cancer. 

Tetrasubstituted pyridazine hedgehog pathway antagonists

The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.

Tetrasubstituted pyridazines hedgehog pathway antagonists

The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. 

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine&#x2014;H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

Histamine H3 receptor agents, preparation and therapeutic uses

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. 

Thiazole pyrazolopyrimidines CRF1 receptor antagonists

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I). 

Growing community of inventors

New Palestine, IN, United States of America

Philip Arthur Hipskind